(Q39050794)

8 September 2017

title

Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer (English)

1 reference

8 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297569%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Andrew George

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297569%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sadaf Ghaem-Maghami

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297569%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Nor Haslinda Abdul Aziz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297569%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Jayanta Chatterjee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297569%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Claudia Hayford

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297569%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Nancy Brewig

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297569%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Lynsey Whilding

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297569%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

3 December 2013

1 reference

Cancer Immunology, Immunotherapy

8 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297569%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297569%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297569%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

215-224

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297569%20AND%20SRC:MED&resulttype=core&format=json

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Tumor Immunotherapy Directed at PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

B7-H1 expression is upregulated in peripheral blood CD14+ monocytes of patients with chronic hepatitis B virus infection, which correlates with higher serum IL-10 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X

B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1503-X